Document is current
Any future updates will be listed below
-
Authors
Kinzie, J. Mark
DeJong, Sandra M.
Edgar, Laura
Houston, L. Joy
Janssen, Furhut
Macaluso, Matthew
Aoun, Elie G.
Bowen, Lynneice
Keepers, George
Bentman, Adrienne L.
Cowley, Deborah S. https://orcid.org/0000-0003-4353-868X
- License Information
-
More Information
Article History
Received: 12 November 2020
Accepted: 7 April 2021
First Online: 16 April 2021
Declarations
:
: Dr. Bentman reports non-financial support from Accreditation Council for Graduate Medical Education (ACGME) - Psychiatry Milestones 2.0 Work Group and non-financial support from ACGME/Psychiatry Review Committee - member, now Vice-Chair, outside the submitted work. Dr. DeJong reports she was Past President of AADPRT when Milestones 2.0 for Psychiatry were developed. Drs. Cowley, Houston, and Kinzie report non-financial support from the Accreditation Council for Graduate Medical Education. Dr. Macaluso has conducted clinical trials research as principal investigator for the following pharmaceutical companies over the last 12 months: (1) Acadia, (2) Allergan, (3) Alkermes, (4) AssureRx/Myriad, (5) Eisai, (6) Lundbeck, (7) Liva Nova, (8) Janssen, (9) Neurim, (10) Otsuka, (11) SAGE pharmaceuticals, and (12) Suven. All clinical trial and study contracts were with and payments made to either the University of Alabama at Birmingham Medical Center or the Kansas University Medical Center Research Institute. From April 2019 to June of 2020, Dr. Macaluso was a member of the speaker bureau for Janssen pharmaceuticals (Spravato/esketamine). Drs. Aoun, Bowen, Edgar, Janssen, and Keepers have nothing to disclose.
Free to read: This content has been made available to all.
